Since Flocks et al. reported impressive responses using diethylstilbestrol-diphosphate in the treatment of advanced prostatic carcinoma, other groups confirmed the significant relief of bone pain in patients previously untreated or in relapse. We treated 24 patients with advanced prostatic carcinoma in progression after a first hormonal manipulation. Progression was defined according the EORTC GU Group response criteria. All patients received daily 500 mg diethylstilbestrol-diphosphate intravenously for 10 days, afterwards they were given three times daily 100 mg p.o. There was no complete or partial objective remission. Pain relief was noted in 16 patients, but was short lived in 7 of them. Fourteen patients stayed in progression. The mean survival time was 4 months (between a few weeks and 23 months). There were no significant cardiovascular side effects. It is concluded that this drug may play a role in the subjective pain relief in the treatment of relapsed prostatic cancer.

Keywords:
Diethylstilbestrol-diphosphate, Prostatic cancer, relapse, Pain
This content is only available via PDF.
© 1988 S. Karger AG, Basel
1988
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.